: iStockAnalyst.com Symbols Feed

Economy & Jobs

Thu, 03 Jan 2008 14:25:31 GMT

Good morning. Ahead of the opening bell, we have a slight positive bias in the premarket futures. While overseas markets are weak following yesterday's poor showing in U.S. equities and higher oil prices, news that workers filing for unemployment benefits fell and a good report from Monsanto (MON) due primarily to strong demand in Latin America has helped. We also have a couple of reports on the employment situation with the released of the ADP employment number (40K vs 33K expectation - last month the ADP reported...[More...]

Daily Record News Briefs: March 13, 2009

Fri, 13 Mar 2009 05:48:00 GMT

Baltimore Opera to liquidate
The Baltimore Opera Company said Thursday it was going to proceed with Chapter 7 bankruptcy, meaning the 58-year old nonprofit will liquidate all of its holdings to pay off creditors.
EntreMed Inc., of Rockville, a biopharmaceutical company, saw its net loss drop in the fourth quarter.

[More...]

Celgene Reports Record Third Quarter 2009 Operating and Financial Results

Thu, 22 Oct 2009 11:46:00 GMT

Celgene Corporation (NASDAQ:CELG):
Celgene Corporation (NASDAQ:CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009.
Based on U.S. GAAP, Celgene reported net income of $216.8 million, or earnings per diluted share of $0.46 for the quarter ended September 30, 2009.

[More...]

EntreMed Reports Second Quarter 2009 Financial Results

Thu, 06 Aug 2009 10:56:00 GMT

EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2009.[More...]

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

Mon, 01 Jun 2009 10:56:00 GMT

Recently Expanded Clinical Program Now Includes Solid and Hematological Malignancies[More...]

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

Fri, 15 May 2009 10:56:00 GMT

ENMD-2076 Clinical Program Adds Leukemia Clinical Study and Orphan Drug Designation[More...]

EntreMed Reports First Quarter 2009 Financial Results

Wed, 06 May 2009 11:48:00 GMT

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three months ended March 31, 2009.
The Company reported a net loss for the first quarter of approximately ($3.5 million), or ($0.04) per share, compared with a net loss of ($8.3 million), or ($0.10) per share, for the same period last year.
Kathy R. Wehmeir-Davis, Principal Accounting Officer, commented on the first quarter results, "The Company's first quarter 2009 financial results were in line with our projections.

[More...]

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

Thu, 12 Mar 2009 10:56:00 GMT

EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2008.[More...]

EntreMed Presents Initial Clinical Results for ENMD-2076

Mon, 09 Feb 2009 10:56:00 GMT

Orphan Drug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum[More...]

EntreMed Focuses on Development of ENMD-2076

Mon, 15 Dec 2008 15:55:00 GMT

Operations and Management Realigned to Provide Full Support for Clinical Activities[More...]

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

Tue, 09 Dec 2008 10:56:00 GMT

EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will serve as principal investigator.[More...]